Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

rivaroxaban, asprin, venous thromboembolism, VTE recurrence, clinical study, ACC.17
News | Antiplatelet and Anticoagulation Therapies | March 23, 2017

March 23, 2017 — In patients at elevated risk for a recurrence of potentially life- threatening blood clots, a low...

PCSK9 inhibitors, bococizumab, ACC .17, clinical trials, LDL cholesterol
News | Pharmaceuticals | March 22, 2017

March 22, 2017 — In a clinical program that was terminated early, the experimental PCSK9 inhibitor bococizumab, when...

RESOLVE study, RESOLVE trial, subclinical leaflet thrombosis

A CT study from the RESOLVE Trial showing valve leaflet thrombosis on a TAVR device. The trial examined a range of surgical and transcatheter valves to show thrombosis is found across both types of devices. It also examined if anticoagulation or antiplatelet therapy could reduce thrombosis and allow a greater range of leaflet motion.

Feature | Heart Valve Technology | March 21, 2017

March 21, 2017 — About 12 percent of patients undergoing aortic valve replacement developed non-symptomatic blood...

Evolocumab, Repatha, LDL, ACC late breaker, best LDL lowering drug
Feature | Pharmaceuticals | March 20, 2017

March 20, 2017 — The most important late-breaking pharmaceutical trial at the 2017 America College of Cardiology...

warfarin, anticoagulation therapy, atrial fibrillation patients, Duke Clinical Research Institute study, stroke
News | Antiplatelet and Anticoagulation Therapies | March 14, 2017

March 14, 2017 — More than 80 percent of stroke patients with a history of...

CeloNova Cobra Pzf stent
Technology | Stents | March 02, 2017

March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc. first-in-class Cobra...

ACC, Haymarket Medical Education, HME, myCME, RightSTEPS initiative, prescribing behavior, chronic heart failure
News | Heart Failure | February 22, 2017

February 22, 2017 — The American College of Cardiology (ACC), Haymarket Medical Education (HME) and myCME have...

Xarelto, rivaroxaban, COMPASS study, ends early,
News | Antiplatelet and Anticoagulation Therapies | February 09, 2017

February 9, 2017 — Janssen Research & Development LLC (Janssen) announced that the Phase 3 COMPASS trial is...

GE Healthcare, Rapiscan stress imaging agent, North America, Rapidscan Pharma Solutions Inc.
News | Pharmaceuticals | February 07, 2017

February 7, 2017 — GE Healthcare’s Life Sciences business announced in January that it acquired Rapidscan Pharma...

The Xprecia Stride Coagulation Analyzer delivers fast, reliable prothrombin time/international normalized ratio (PT/INR) testing for point-of-care monitoring and management of oral anticoagulation therapy with warfarin, a vitamin K antagonist. It is the latest INR testing system to enter the market in late 2016. Read the article “Siemens Receives FDA Clearance of Xprecia Stride Coagulation Analyzer.”
 

 

Feature | Point of Care Testing | December 30, 2016 | Ravi Chawat

Point of care testing devices are gaining widespread approval for prompt medical diagnoses, especially in cardiology...

Heart attack, heart failure, Cimaglermin
News | Pharmaceuticals | December 28, 2016

December 28, 2016 — Cimaglermin, a new experimental drug, may help restore cardiac function after heart failure,...

harmful drug interactions, big data, JACC study, drug-drug interaction, Nicholas Tatonetti
News | Pharmaceuticals | December 13, 2016

December 13, 2016 — Coupling data mining of adverse event reports and electronic health records with targeted...

INRatio, Alere, Abbott, I and R testing, INR testing
Feature | Point of Care Testing | December 07, 2016

December 7, 2016 — Abbott has filed a complaint to terminate its proposed acquisition of Alere based on the...

Overlay Init